Prevalence of TP53 gene mutation accounts for nearly 39% of ADC, 51% of SCC, 68% of large cell carcinoma (LCC), and 80% of small cell lung cancer (SCLC) [34, 36]. This evidence concerns the gene TP53 and leukoencephalopathy with calcifications and cysts.